Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs…
The global “diabesity” market is swelling into a once‑in‑a‑generation opportunity, and Eli Lilly, Novo Nordisk—and now a new class of device innovators like Modular Medical (NASDAQ: MODD)—are still lacing up their running shoes rather than sprinting for the finish line. For investors,…
Tandem Diabetes Care’s (TNDM) latest trip to the capital markets reads less like a distress signal and more like a company quietly extending its runway in a race it fully intends to finish. At the same time, a familiar name in diabetes…
Insulet’s (PODD) latest numbers read like the balance sheet of a very determined racehorse: fast, disciplined, and still eager for the next lap, even as a promising upstart named Modular Medical trots onto the same track.
Insulet’s Earnings: Hitting a Full Gallop…
Modular Medical’s (NASDAQ: MODD) Pivot insulin delivery system is quietly building a credible bull case that now extends beyond regulatory momentum and leadership credentials into hard operational execution. With the company achieving a key manufacturing milestone for its Pivot tubeless insulin patch…